[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-350103-105":59,"doc-detail-350103-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","sodium-glucose-co-transporter-2-inhibitors-and-obesity-associated-cancers-in-people-with-type-2-diabetes-a-real-world-observational-study","Sodium-glucose co-transporter 2 inhibitors and obesity-associated cancers in people with type 2 diabetes: A real-world observational study","","The study investigates whether sodium-glucose co-transporter 2 inhibitors (SGLT-2i) are associated with obesity-associated cancers (OAC) in individuals with type 2 diabetes (T2D). Using a retrospective cohort design with TriNetX US Collaborative Network data, SGLT-2i initiators were compared with dipeptidyl peptidase-4 inhibitors (DPP-4i) initiators via 1:1 propensity score matching. Prior cancer or cancer diagnosed within 6 months was excluded; Cox proportional hazards models estimated hazard ratios and 95% confidence intervals across OAC types and all-cancer outcomes.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/sodium-glucose-co-transporter-2-inhibitors-and-obesity-associated-cancers-in-people-with-type-2-diabetes-a-real-world-observational-study/350103/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/sodium-glucose-co-transporter-2-inhibitors-and-obesity-associated-cancers-in-people-with-type-2-diabetes-a-real-world-observational-study/350103.png","ImageObject",300,407,{"name":92,"@type":93},"Sophia Brooks","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-05","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What was the aim of the study?","Question",{"text":113,"@type":114},"To investigate the association between SGLT-2 inhibitors (SGLT-2i) and obesity-associated cancers (OAC) in individuals with type 2 diabetes (T2D).","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How were participants and comparison groups defined?",{"text":118,"@type":114},"Individuals with T2D initiating SGLT-2i were compared with those initiating dipeptidyl peptidase-4 inhibitors (DPP-4i) using 1:1 propensity score matching to address key confounders; prior cancer and cancer diagnosed within 6 months were excluded.",{"name":120,"@type":111,"acceptedAnswer":121},"What were the main findings for OAC and specific cancer outcomes?",{"text":122,"@type":114},"SGLT-2i initiation was not associated with composite OACs versus DPP-4i overall or by overweight/obesity status. Renal cancer was observed at a lower rate, while thyroid cancer showed a higher rate; all-cancer outcomes showed modest reductions.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},350103,1790826141,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":41,"preview_page_count":19,"preview_urls":146},962084925636,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","DOI: 10.1111/dom.70562  \nO R IG INA L ARTI CLE  \nSodium-glucose co-transporter 2 inhibitors and obesityassociated cancers in people with type 2 diabetes: A real-world observational study  \nTestimony Ipaye MSc 1,2,3  | Jonathan Goldney MRCP(UK) 1,2  |  \nThomas Yates PhD 1,2 | Francesco Zaccardi PhD 1,2,4 | Kamlesh Khunti PhD 1,2  | Elina Akalestou PhD 5,6 | Melanie J. Davies PhD 1,2  | Karen Brown PhD 1,3 | Dimitris Papamargaritis PhD 1,2  \n1NIHR Leicester Biomedical Research Centre, University Hospitals of Leicester NHS Trust, Leicester, UK 2Leicester Diabetes Centre, Leicester General Hospital, University of Leicester, Leicester, UK 3Leicester Cancer Research Centre, University of Leicester, Leicester, UK  \n4Leicester Real World Evidence Unit, Leicester, UK  \n5Division of Cardiovascular Sciences, College of Life Sciences, University of Leicester, Leicester, UK  \n6Section of Cell Biology and Functional Genomics, Division of Diabetes, Endocrinology and Metabolism, Department of Metabolism, Digestion and Reproduction, Imperial College London, London, UK  \nCorrespondence  \nJonathan Goldney, NIHR Leicester Biomedical Research Centre, University Hospitals of Leicester NHS Trust, Leicester, LE5 4PW, UK.  \nEmail: [jg465@leicester.ac.uk](jg465@leicester.ac.uk)  \nFunding information  \nNIHR Leicester Biomedical Research Centre; University of Leicester; National Institute for Health Research Applied Research Collaboration East of England, Grant/Award Number: ARC EM; British Heart Foundation, Grant/Award Number: AA/18/3/34220; Wellcome Trust Leicestershire Healthcare Inequalities Improvement Doctoral Training Programme, Grant/Award Number: 223512/ Z/21/Z  \nAbstract  \nAims: To investigate the association between sodium-glucose co-transporter 2 inhibitors (SGLT-2i) and obesity-associated cancers (OAC) in individuals with type 2 diabetes (T2D) .  \nMaterials and Methods: This retrospective cohort study used data from the TriNetX US Collaborative Network. Individuals with T2D initiating SGLT-2i were compared with those initiating dipeptidyl peptidase-4 inhibitors (DPP-4i) using 1:1 propensity score matching to account for key confounders. Individuals with prior cancer or cancer diagnosed within 6 months after treatment initiation were excluded. Hazard ratios (HRs) and 95% confidence intervals (CIs) for composite OAC, individual OAC types, and all-cancer outcomes were estimated using Cox proportional hazards models. Analyses were conducted at the overall cohort, stratified by overweight/ obesity status and across individual SGLT-2i agents.  \nResults: Initiation of SGLT-2i was not associated with composite OACs compared with DPP-4i in the overall population or across overweight/obesity status. A lower rate of renal cancer was also observed in the overall population (HR 0.78; 95% CI 0.67–0.92) and among individuals with overweight/obesity (0.79; 0.66–0.93), while a higher rate of thyroid cancer was observed in the overall population (1.37; 1.06–1. 76) . Modest reductions in the all-cancer outcome was observed in the overall  \nThis is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.  \n© 2026 The Author(s) . Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd.  \nDiabetes Obes Metab. 2026;28:3807–[3818.](3818. wileyonlinelibrary.com/journal/dom)[ wileyonlinelibrary.com/journal/dom](3818. wileyonlinelibrary.com/journal/dom)  3807  \npopulation (0 .96; 0 .93–0.99) and among individuals with (0 .95; 0 .91–0.98) and without (0 .88; 0 .78–0.99) overweight/obesity.  \nConclusion: In this large real-world study of individuals with T2D, initiation of SGLT- 2i was not associated with higher or lower rates of OAC compared with DPP-4i. However, initiation of SGLT-2i was associated with a modestly lower rate of the allcancer outcome, the clinical significance of which remains unclear.  \nKEYWOR DS  \ncancer","cbCailsLYg82cqHu","https://ap.wps.com/l/cbCailsLYg82cqHu","pdf",2012353,12,"English","# Abstract\n## Aims\n## Materials and Methods\n## Results\n## Conclusion\n# Introduction","[{\"question\":\"What was the aim of the study?\",\"answer\":\"To investigate the association between SGLT-2 inhibitors (SGLT-2i) and obesity-associated cancers (OAC) in individuals with type 2 diabetes (T2D).\"},{\"question\":\"How were participants and comparison groups defined?\",\"answer\":\"Individuals with T2D initiating SGLT-2i were compared with those initiating dipeptidyl peptidase-4 inhibitors (DPP-4i) using 1:1 propensity score matching to address key confounders; prior cancer and cancer diagnosed within 6 months were excluded.\"},{\"question\":\"What were the main findings for OAC and specific cancer outcomes?\",\"answer\":\"SGLT-2i initiation was not associated with composite OACs versus DPP-4i overall or by overweight/obesity status. Renal cancer was observed at a lower rate, while thyroid cancer showed a higher rate; all-cancer outcomes showed modest reductions.\"}]","Sodium-glucose co-transporter 2 inhibitors and obesity-associated cancers in people with type 2 diabetes: A real-world observational study | PDF",1790087197,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8324c623d7573f5846a2c134de56571d.webp",983,1291,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8f5d3932ba989c85bda80ee0be8531f3.webp",982,1290,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/45a9b82cc09d5a56069148fe5216a0e0.webp",981,1289,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c7dd6dba0841b51e12c7e7ad390a866e.webp",980,1287]